Nkarta, Inc. Common Stock (NKTX) Stock Price

NKTXStock
$2.76+25.45%52W
Market Cap$197.68M
P/E
PEG Ratio
Div yield
Beta0.94

NKTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.97%
Price vs S&P 500 (4W)26.83%
VGM Score57.59

NKTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.36-$0.54-48.63%(-$0.18)
Q4 2025-$0.29-$0.37-25.42%(-$0.08)
Q3 2025-$0.31-$0.29+7.45%(+$0.02)
Q2 2025-$0.35-$0.31+11.43%(+$0.04)

NKTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.30
4.25
4.25

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
NKTXNkarta, Inc. Common Stock
C$2.76
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Nkarta, Inc. Common Stock

Nkarta is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic natural killer (NK) cell therapies for cancer treatment. The company combines proprietary NK cell expansion technology with engineered cell recognition capabilities to enhance therapeutic targeting and persistence. This approach aims to generate an abundant supply of engineered NK cells that can identify and eliminate cancer cells while triggering durable immune responses.